您现在的位置:http://bvbarreiro.thisfunctional.pt/wp-content/plugins/twentytwentyseven/>online games like y8
super 8 game
Tibbetts: It's time to crown some Buffalo Bills midseason MVPsTrudeau told Trump Americans would also suffer if tariffs are imposed, a Canadian minister saysStoli vodka files for bankruptcy in the United StatesCold-case team seeks to link trace evidence to suspected victim of serial killer Warren Forrest
Baltimore quarterback Lamar Jackson, the reigning NFL Most Valuable Player, leads fan balloting for the 2025 NFL Pro Bowl Games after one week of voting, the league announced on Monday. Ravens superstar Jackson set the overall pace with 44,681 votes followed by teammate Derrick Henry, the running back leader, in second overall at 40,729 votes. Philadelphia Eagles running back Saquon Barkley was third overall at 40,602, only 127 votes behind Henry in the rusher's race, with Buffalo quarterback Josh Allen fourth overall on 36,574 and Detroit running back Jahmyr Gibbs fifth on 35,637. The Detroit Lions lead all clubs in total votes received, followed by the Ravens, the two-time defending Super Bowl champion Kansas City Chiefs, the Minnesota Vikings and Pittsburgh Steelers. The NFL's revamped all-star event will be staged in Orlando, Florida, for the second consecutive year. In all, 88 players will gather on February 2 in skills competitions and a flag football showdown with coaches Peyton and Eli Manning. While other vote totals were not revealed, Washington rookie Jayden Daniels was the top NFC quarterback in the fan voting and top receivers were Minnesota's Justin Jefferson in the NFC and Cincinnati's Ja'Marr Chase in the AFC. NFL fans can vote as often as they wish through December 23 with selections decided by a consensus of ballots by players, coaches and fans with each group counting for one-third of every player's final total. NFL players and coaches will cast votes on December 27. js/rcw
Japan holds first memorial for 'all workers' at Sado gold mines but blurs WWII atrocity. Why?
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. NSPR , developer of the CGuardTM Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott ABT in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his insights will be invaluable as the Company rapidly approaches potential U.S. approval of CGuard Prime, the most significant value inflection point in its history. I look forward to Scott's contributions and believe he will have an immediate impact." Marvin Slosman, Chief Executive Officer of InspireMD and Board member, commented, "The addition of Scott to our Board adds tremendous experience in the cardiovascular field, with a track record of growth and innovation as an executive, a board member and investor. His experience and legacy in the space will help guide us through our next stages of advancing our novel carotid platform as part of a comprehensive approach to catalyzing on the market shift toward a stent first standard while also guiding our pipeline of innovation, including our CAS, TCAR and Neuro focus." "I am very excited to join the InspireMD Board at such a transformational time for the company," added Mr. Ward. "With an impressive body of data demonstrating the superior short- and long-term patient outcomes of its novel CGuard Prime carotid stent system, I believe that CGuard, when approved in the U.S., will quickly become a new standard-of-care for carotid intervention and stroke prevention. I look forward to working with my fellow Board members and the InspireMD leadership team to achieve this goal." Mr. Ward has over 40 years of experience in the healthcare industry, including nearly 30 years at Medtronic, Inc. where he served in various leadership roles including as Senior Vice President and President of the CardioVascular, Neurological and Diabetes businesses. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology and life science companies. He earned his Bachelor of Science in Genetics and Cell Biology, his Master of Science in Toxicology, and his Master of Business Administration, all from the University of Minnesota. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet ® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD's common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com . Forward-looking Statements This press release contains "forward-looking statements." Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential", "scheduled" or similar words. Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team's or directors' expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch.. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company's control, and cannot be predicted or quantified and consequently; actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives, and substantial doubt regarding our ability to continue as a going concern; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute our stockholders' ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Investor Contacts: Craig Shore Chief Financial Officer InspireMD, Inc. 888-776-6804 craigs@inspiremd.com Chuck Padala, Managing Director LifeSci Advisors 646-627-8390 chuck@lifesciadvisors.com investor-relations@inspiremd.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Broncos, left tackle Garett Bolles agree on 4-year extension to protect rookie quarterback Bo NixTrent Williams' wife, Sondra, says their son was stillborn SANTA CLARA, Calif. (AP) — The San Francisco 49ers were hit by another family tragedy with the announcement that star left tackle Trent Williams' wife gave birth to a stillborn son late last week. Josh Dubow, The Associated Press Dec 2, 2024 3:13 PM Dec 2, 2024 3:35 PM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message FILE - San Francisco 49ers offensive tackle Trent Williams (71) and teammates take the field for an NFL football game against the New England Patriots, Sept. 29, 2024, in Santa Clara, Calif. (AP Photo/Godofredo A. Vásquez, file) SANTA CLARA, Calif. (AP) — The San Francisco 49ers were hit by another family tragedy with the announcement that star left tackle Trent Williams' wife gave birth to a stillborn son late last week. Sondra Williams announced on Instagram on Sunday that she gave birth to Trenton O’Brien Williams Jr. on Nov. 24. Williams also wrote that she was initially pregnant with twins and lost the other child earlier in the pregnancy. “I can’t even begin to describe how I felt leaving the hospital without you,” she wrote. “Nor how it feels being home celebrating Thanksgiving without my baby in my arms. My heart is broken and my arms are empty. But I know you’ll always be near watching over me and your sisters. And for that, my heart smiles with gratitude. Thank God for allowing us to bond for 35 weeks and for me to birth you so I could hold you in my arms. I’m at peace knowing you will never have to suffer.” Williams wrote that her son was diagnosed with Trisomy 13, a genetic condition also known as Patau syndrome that affects how the face, brain and heart develop, along with several other internal organs. Trent Williams spent time last week at the hospital and grieving with his family, including the couple's three young daughters. “He was there at the hospital with her and got to meet him and say bye,” coach Kyle Shanahan said Monday. "Then he had to cremate him on Friday. So he’s been dealing with that and he’s working through it. But we’re all just trying to be here for him through it all.” This is the second tragedy to hit the Niners in recent weeks. Cornerback Charvarius Ward's 1-year-old daughter , Amani Joy, died on Oct. 28. She had born prematurely with Down syndrome and had open-heart surgery in April 2023. Ward spent a few weeks away from the team and returned to the field for the first time on Sunday. Williams has missed the last two games with an ankle injury but Shanahan said he is hoping to be able to the return as soon as he's healthy. “It’s hard as a coach. It’s hard as a friend. It’s hard as a family member. It’s hard for everybody," Shanahan said. ”But we spend a lot of time with each other. That’s what’s cool about a football team. Whatever you go through, the good or the bad, we go through it together. I do like that they have a group of guys they can go to, a group of guys that can see them every day. You can never escape that full grief and stuff. But I do think it’s nice for those guys to have another avenue to get out on the football field, to get around teammates and things like that." ___ AP NFL: https://apnews.com/hub/nfl Josh Dubow, The Associated Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Get your daily Victoria news briefing Email Sign Up More Football (NFL) NFL Inactive Report Dec 2, 2024 3:52 PM Rams finally ran the ball well in New Orleans, and it kept them in the playoff race Dec 2, 2024 3:37 PM Justin Tucker's erratic season isn't getting any better, and it's hurting Baltimore's outlook Dec 2, 2024 3:32 PM
上一篇:sonic super game
- 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
- 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。